Side effects and relief methods of Pemigatinib
Pemigatinib is an FGFR inhibitor mainly used to treat malignant tumors such as cholangiocarcinoma. Its common side effects include hyperphosphatemia, ocular abnormalities, and gastrointestinal reactions, which need to be managed through dose adjustment, symptomatic treatment, and regular monitoring.
1. Common side effects and mitigation methods
(1) Hyperphosphatemia: manifested as elevated blood phosphorus, which can be relieved by a low phosphorus diet, phosphorus binders, or temporary discontinuation of medication. In severe cases, permanent discontinuation of medication is necessary.
(2) Eye abnormalities: including retinal detachment and blurred vision, require regular eye examinations, suspend medication and seek medical attention when symptoms appear.
(3) Gastrointestinal reactions: Diarrhea and nausea can be relieved by antiemetic drugs, fluid replacement, and divided feeding. For severe cases, the dosage needs to be adjusted.
2. Hematological system side effects
(1) Anemia: Regularly monitor hemoglobin and provide erythropoietin or transfusion support if necessary.
(2) Thrombocytopenia: To avoid trauma, use a soft bristled toothbrush. In severe cases, platelet transfusions or medication should be discontinued.
3. Skin related side effects
(1) Rash: Keep the skin moist, avoid sun exposure, use mild skincare products, and treat moderate to severe rashes locally or orally with steroids.
(2) Paronychia: Keep hands and feet clean and dry, avoid biting nails, and seek antibiotic treatment in case of infection.
4. Special monitoring requirements
(1) Blood phosphorus monitoring: Weekly testing during the initial stage of treatment, and once a month after stabilization, adjust diet or medication based on the results.
(2) Ophthalmic examination: Baseline and fundus examination every 2 months, with immediate evaluation in case of visual changes.
5. Serious side effect management
(1) Interstitial lung disease: If coughing and difficulty breathing occur, medication should be stopped immediately and hormone therapy should be given.
(2) Hepatotoxicity: Regularly monitor liver function. If ALT/AST levels increase by more than 3, medication should be suspended until recovery.
Disclaimer：《Side effects and relief methods of Pemigatinib》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！